Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director Christopher Viehbacher acquired 83,333 shares of the stock in a transaction on Friday, August 7th. Braveheart Bio Stock PerformanceShares of Braveheart Bio stock traded up $0.20 on Friday, hitting $30.00. Braveheart Bio, Inc. has a one year low of $28.47 and a one year high of $32.00. Get Braveheart Bio alerts:About Braveheart Bio(Get Free Report)Read MoreWe are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.